Kyowa Hakko’s Parkinson’s Drug Is Not Approvable – U.S. FDA

Kyowa Hakko will work with U.S. FDA to determine a path forward for its Parkinson's treatment istradefylline (KW-6002) after receiving a "not approvable" letter from the agency Feb. 25, the Tokyo-based firm said Feb. 27